Galectin Targeted Therapy in Oncology: Current Knowledge and Perspectives

Area of Science:

• Oncology
• Glycobiology
• Molecular Biology

Background:

• Cancer incidence and mortality are rising, posing a significant therapeutic challenge despite advances in understanding the disease.
• Current cancer therapies target various aspects like growth and metastasis, but many underlying mechanisms remain unknown, limiting treatment efficacy.
• Emerging research highlights the role of glycans and galectins in carcinogenesis, suggesting new avenues for therapeutic intervention.

Purpose of the Study:

• To review the current understanding of galectin-glycan interactions in cancer.
• To explore the mechanism of action of galectins in cancer development, metastasis, and immunity.
• To discuss the potential of galectins as prognostic markers and therapeutic targets in oncology.

Main Methods:

• Literature review of recent studies on galectins, glycans, and cancer.
• Analysis of the molecular mechanisms underlying galectin-glycan interactions in carcinogenesis.
• Examination of galectin's role in metastasis, angiogenesis, tumor immunity, proliferation, and apoptosis.

Main Results:

• Galectins, characterized by their carbohydrate recognition domain (CRD), bind to specific oligosaccharide chains (glycans) on cell surfaces.
• The galectin-glycan complex is crucial for key cancer processes including metastasis, angiogenesis, immune evasion, proliferation, and apoptosis.
• Galectins show prognostic value in several neoplasms, aiding in predicting patient outcomes and guiding treatment decisions.

Conclusions:

• Galectin-glycan interactions are fundamental to cancer progression and represent a significant area for therapeutic development.
• Inhibitors targeting galectin binding, such as carbohydrates and antibodies, are being explored as novel cancer therapies.
• Further research into galectins' mechanisms and therapeutic potential is warranted for improved cancer treatment strategies.